Icell Kealex Therapeutics Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 1

Icell Kealex Therapeutics General Information

Description

Developer of T-cell engager-armed oncolytic virus intended for the treatment of solid tumors. The company is combining vaccinia virus (VV) with T-cell-based immunotherapy loading it with T-cell engagers, creating T-cell engager-armed oncolytic vaccinia virus, helping healthcare service providers to treat their patients easily.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Primary Office
  • 2450 Holcombe Boulevard
  • Houston, TX 77021
  • United States
+1 (346) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Icell Kealex Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator 02-Mar-2016 Completed Generating Revenue
To view Icell Kealex Therapeutics’s complete valuation and funding history, request access »

Icell Kealex Therapeutics Patents

Icell Kealex Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019367965-A1 Mutant vaccinia viruses and use thereof Pending 22-Oct-2018 0000000000
CA-3117378-A1 Mutant vaccinia viruses and use thereof Pending 22-Oct-2018 0000000000
EP-3870217-A1 Mutant vaccinia viruses and use thereof Pending 22-Oct-2018 0000000000
EP-3870217-A4 Mutant vaccinia viruses and use thereof Pending 22-Oct-2018 0000000000 0
US-20210388388-A1 Mutant vaccinia viruses and use thereof Pending 22-Oct-2018 C07K14/005
To view Icell Kealex Therapeutics’s complete patent history, request access »

Icell Kealex Therapeutics Executive Team (2)

Name Title Board Seat Contact Info
Shautong Song Founder & Co-Chief Executive Officer
Xiao-Tong Song Co-Founder
To view Icell Kealex Therapeutics’s complete executive team members history, request access »

Icell Kealex Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Johnson & Johnson Innovation - JLABS Accelerator/Incubator 000 0000 000000 0
To view Icell Kealex Therapeutics’s complete investors history, request access »